Fig. 5

Hypo-MS4 is a signature of tumor immune responses that is associated with distant metastasis. A Comparison of neoantigen load between tumors of low and high Hypo-MS4 activity in four cancer types. B Correlation analysis of the fraction of cancer cells with high Hypo-MS4 activity and the fraction of CD4 + regulatory T cells in melanoma. C Fractions of cancer cells with high Hypo-MS4-GES scores in primary lesions and lymph node metastases from patients with colorectal cancer in single-cell methylome datasets of three patients, CRC01, CRC02, and CRC10. D Differences in Hypo-MS4 activity in responders and nonresponders to ICI therapy (Wilcoxon’s rank sum test) according to two methylome sequencing studies of melanoma patients. E Hypo-MS4-GES score in responders and nonresponders to ICI therapy (Wilcoxon’s rank sum test), in patients with gastric cancer (Kim et al. (2018) [45]) and in patients with melanoma (Liu et al. (2019) [46]; Riaz et al. (2017) [47]). F Fraction of Hypo-MS4-positive cells in ICI therapy responders and nonresponders (Wilcoxon’s rank sum test) before and after ICI treatment based on the single-cell transcriptome of melanoma